PMHNP BOARD REVIEW EXAMINATION
Advanced Psychopharmacology, Reproductive Psychiatry, and Valproic
Acid Teratogenicity
Comprehensive 200-Question Examination with Detailed Rationales
Designed for Psychiatric-Mental Health Nurse Practitioner Candidates
,PMHNP Comprehensive Examination: Valproic Acid & Reproductive Safety
This comprehensive 200-question professional examination is tailored for
Psychiatric-Mental Health Nurse Practitioners (PMHNPs). It rigorously covers
advanced psychopharmacology, teratogenic risks of valproic acid
(depakote/divalproex sodium) including neural tube defects (spina bifida),
congenital malformations, cognitive/neurodevelopmental sequelae, informed
consent protocols, preconception counseling, and evidence-based alternatives for
bipolar disorder during pregnancy.
Domain 1: Teratogenic Mechanisms and Neural Tube Defects
Valproic acid exposure during the first trimester is uniquely associated
with an elevated risk of neural tube defects, specifically spina bifida
(e.g., myelomeningocele), due to interference with folate metabolism and
histone deacetylase inhibition.
Question 1: A 28-year-old female with bipolar I disorder stabilized on
divalproex sodium (Depakote) 1000 mg daily informs the PMHNP that
she and her husband are planning to conceive within the next three
months. Which congenital malformation carries the highest relative risk
and definitive association with first-trimester valproic acid exposure?
A. Transposition of the great arteries
B. Neural tube defects (specifically spina bifida /
myelomeningocele)
C. Congenital hypothyroidism
D. Bilateral renal agenesis (Potter sequence)
Rationale: Valproic acid exposure during organogenesis
(specifically the first trimester, weeks 3-4 post-conception) is strongly
associated with an increased incidence of neural tube defects, most
notably spina bifida, occurring in approximately 1% to 2% of
exposed fetuses (a 10-20 fold increase over the general population).
,Question 2: During preconception counseling regarding valproic acid,
the PMHNP explains the embryological mechanism of neural tube
defects. At approximately what gestational age does neural tube closure
typically occur, rendering the embryo most vulnerable to valproate-
induced disruption?
A. Gestational weeks 1 to 2
B. Gestational weeks 3 to 4 (days 21-28 post-conception)
C. Gestational weeks 8 to 12
D. Gestational weeks 16 to 20
Rationale: Neural tube closure occurs between the 3rd and 4th weeks
after conception (days 21 to 28), which frequently coincides with the
time a woman realizes she has missed a menstrual period,
emphasizing the critical need for pre-pregnancy counseling and
effective contraception.
Question 3: A patient taking valproic acid who becomes unexpectedly
pregnant asks why high-dose folic acid supplementation was not
completely protective against neural tube defects. What is the
pharmacological basis of valproate-induced neural tube defects?
A. Pure folate receptor antagonism identical to methotrexate
B. Multifactorial mechanisms including folate pathway
disruption, histone deacetylase (HDAC) inhibition, and oxidative
stress
C. Direct suppression of fetal thyroid-stimulating hormone receptors
D. Unchecked induction of maternal hepatic CYP3A4 enzymes
depleting vitamin B12
Rationale: While folate antagonism plays a role, valproate
teratogenicity is complex, involving histone deacetylase inhibition,
perturbation of intracellular inositol, and induction of oxidative
, stress in neuroepithelial cells, which is why standard folic acid does
not entirely eliminate risk.
Question 4: Clinical Case 4: A patient taking valproic acid for bipolar
disorder plans pregnancy. Which specialized prenatal diagnostic
screening test is specifically indicated at 15-20 weeks gestation to screen
for valproate-associated neural tube defects?
A. First-trimester nuchal translucency ultrasound only
B. Maternal serum alpha-fetoprotein (MSAFP) assay and
targeted detailed anatomical ultrasound
C. Routine serial maternal blood glucose tolerance testing
D. Third-trimester biophysical profile starting at 28 weeks
Rationale: Maternal serum alpha-fetoprotein (MSAFP) elevation
combined with a targeted level-II anatomical ultrasound is the gold
standard for screening and diagnosing open neural tube defects such
as spina bifida andencephaly in high-risk pregnancies.
Question 5: Clinical Case 5: A patient taking valproic acid for bipolar
disorder plans pregnancy. Which specialized prenatal diagnostic
screening test is specifically indicated at 15-20 weeks gestation to screen
for valproate-associated neural tube defects?
A. First-trimester nuchal translucency ultrasound only
B. Maternal serum alpha-fetoprotein (MSAFP) assay and
targeted detailed anatomical ultrasound
C. Routine serial maternal blood glucose tolerance testing
D. Third-trimester biophysical profile starting at 28 weeks
Rationale: Maternal serum alpha-fetoprotein (MSAFP) elevation
combined with a targeted level-II anatomical ultrasound is the gold
standard for screening and diagnosing open neural tube defects such
as spina bifida andencephaly in high-risk pregnancies.
Advanced Psychopharmacology, Reproductive Psychiatry, and Valproic
Acid Teratogenicity
Comprehensive 200-Question Examination with Detailed Rationales
Designed for Psychiatric-Mental Health Nurse Practitioner Candidates
,PMHNP Comprehensive Examination: Valproic Acid & Reproductive Safety
This comprehensive 200-question professional examination is tailored for
Psychiatric-Mental Health Nurse Practitioners (PMHNPs). It rigorously covers
advanced psychopharmacology, teratogenic risks of valproic acid
(depakote/divalproex sodium) including neural tube defects (spina bifida),
congenital malformations, cognitive/neurodevelopmental sequelae, informed
consent protocols, preconception counseling, and evidence-based alternatives for
bipolar disorder during pregnancy.
Domain 1: Teratogenic Mechanisms and Neural Tube Defects
Valproic acid exposure during the first trimester is uniquely associated
with an elevated risk of neural tube defects, specifically spina bifida
(e.g., myelomeningocele), due to interference with folate metabolism and
histone deacetylase inhibition.
Question 1: A 28-year-old female with bipolar I disorder stabilized on
divalproex sodium (Depakote) 1000 mg daily informs the PMHNP that
she and her husband are planning to conceive within the next three
months. Which congenital malformation carries the highest relative risk
and definitive association with first-trimester valproic acid exposure?
A. Transposition of the great arteries
B. Neural tube defects (specifically spina bifida /
myelomeningocele)
C. Congenital hypothyroidism
D. Bilateral renal agenesis (Potter sequence)
Rationale: Valproic acid exposure during organogenesis
(specifically the first trimester, weeks 3-4 post-conception) is strongly
associated with an increased incidence of neural tube defects, most
notably spina bifida, occurring in approximately 1% to 2% of
exposed fetuses (a 10-20 fold increase over the general population).
,Question 2: During preconception counseling regarding valproic acid,
the PMHNP explains the embryological mechanism of neural tube
defects. At approximately what gestational age does neural tube closure
typically occur, rendering the embryo most vulnerable to valproate-
induced disruption?
A. Gestational weeks 1 to 2
B. Gestational weeks 3 to 4 (days 21-28 post-conception)
C. Gestational weeks 8 to 12
D. Gestational weeks 16 to 20
Rationale: Neural tube closure occurs between the 3rd and 4th weeks
after conception (days 21 to 28), which frequently coincides with the
time a woman realizes she has missed a menstrual period,
emphasizing the critical need for pre-pregnancy counseling and
effective contraception.
Question 3: A patient taking valproic acid who becomes unexpectedly
pregnant asks why high-dose folic acid supplementation was not
completely protective against neural tube defects. What is the
pharmacological basis of valproate-induced neural tube defects?
A. Pure folate receptor antagonism identical to methotrexate
B. Multifactorial mechanisms including folate pathway
disruption, histone deacetylase (HDAC) inhibition, and oxidative
stress
C. Direct suppression of fetal thyroid-stimulating hormone receptors
D. Unchecked induction of maternal hepatic CYP3A4 enzymes
depleting vitamin B12
Rationale: While folate antagonism plays a role, valproate
teratogenicity is complex, involving histone deacetylase inhibition,
perturbation of intracellular inositol, and induction of oxidative
, stress in neuroepithelial cells, which is why standard folic acid does
not entirely eliminate risk.
Question 4: Clinical Case 4: A patient taking valproic acid for bipolar
disorder plans pregnancy. Which specialized prenatal diagnostic
screening test is specifically indicated at 15-20 weeks gestation to screen
for valproate-associated neural tube defects?
A. First-trimester nuchal translucency ultrasound only
B. Maternal serum alpha-fetoprotein (MSAFP) assay and
targeted detailed anatomical ultrasound
C. Routine serial maternal blood glucose tolerance testing
D. Third-trimester biophysical profile starting at 28 weeks
Rationale: Maternal serum alpha-fetoprotein (MSAFP) elevation
combined with a targeted level-II anatomical ultrasound is the gold
standard for screening and diagnosing open neural tube defects such
as spina bifida andencephaly in high-risk pregnancies.
Question 5: Clinical Case 5: A patient taking valproic acid for bipolar
disorder plans pregnancy. Which specialized prenatal diagnostic
screening test is specifically indicated at 15-20 weeks gestation to screen
for valproate-associated neural tube defects?
A. First-trimester nuchal translucency ultrasound only
B. Maternal serum alpha-fetoprotein (MSAFP) assay and
targeted detailed anatomical ultrasound
C. Routine serial maternal blood glucose tolerance testing
D. Third-trimester biophysical profile starting at 28 weeks
Rationale: Maternal serum alpha-fetoprotein (MSAFP) elevation
combined with a targeted level-II anatomical ultrasound is the gold
standard for screening and diagnosing open neural tube defects such
as spina bifida andencephaly in high-risk pregnancies.
